Welcome to our dedicated page for Organigram Global news (Ticker: OGI), a resource for investors and traders seeking the latest updates and insights on Organigram Global stock.
News about Organigram Global Inc. (NASDAQ: OGI, TSX: OGI) focuses on its activities as a Canadian cannabis cultivator, manufacturer and brand owner operating under the Cannabis Act and Cannabis Regulations. Company announcements highlight its position as Canada’s number one cannabis company by market share in the recreational segment, as well as developments across cultivation, product innovation, beverages and international expansion.
Investors and observers following OGI news will see regular updates on quarterly and annual financial results, including net revenue trends, adjusted gross margin, adjusted EBITDA and free cash flow, as reported in its earnings releases. These updates often discuss the impact of acquisitions such as Motif Labs Ltd. and Collective Project Limited on revenue growth, extraction capabilities and beverage market participation, along with commentary on cost efficiencies and synergy realization.
Organigram’s news flow also covers product and brand launches. Examples include new SHRED gummies formats, Big Bag O’ Buds strains, BOXHOT infused pre-rolls, Trailblazer blunts, Rizzlers vapes and the happly hemp-derived THC brand in the United States. The company highlights its use of FAST™ nanoemulsion technology in ingestible products and describes how these offerings are designed around consumer preferences, including mood-based formulations.
Another important theme in Organigram news is international and policy-related activity. Releases describe record international sales, progress toward EU-GMP certification for the Moncton facility, exclusive genetics agreements with Phylos Bioscience Inc., and polling and economic reports that position legal cannabis as a contributor to Canada’s GDP, jobs and innovation. Corporate governance and leadership updates, such as CEO succession plans and executive appointments, are also communicated through news releases. For a fuller picture of OGI’s evolving strategy and operations, readers can review this ongoing stream of company disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Organigram Holdings (NASDAQ: OGI) reported strong financial results for Q2 Fiscal 2023, achieving net revenue of $39.5 million, a 24% increase from $31.8 million in the same quarter last year. The adjusted gross margin improved to $13.4 million (34%), up from $8.3 million (26%). Notably, the company posted an adjusted EBITDA of $5.6 million, marking the fifth consecutive quarter of positive results, compared to $1.6 million in Q2 Fiscal 2022. Despite facing pricing pressures, particularly in large format flower SKUs, Organigram anticipates continued growth, with expectations for higher revenues in Q3 Fiscal 2023 driven by innovation and expanded product lines.
Organigram Holdings Inc. (NASDAQ: OGI) announced it will report second quarter fiscal 2023 earnings results on April 11, 2023, after market close. A conference call is scheduled for April 12, 2023, at 8:00 am ET to discuss the financial outcomes. Investors will have the opportunity to register for the call in advance to receive details via email. The company, which is a leading cannabis producer in Canada, emphasized its focus on high-quality cannabis production and global partnerships. It holds a portfolio of brands catering to both recreational and medical markets.